Rigiscan Evaluation of Men with Diabetes Mellitus and Erectile Dysfunction and Correlation with Diabetes Duration, Age, BMI, Lipids and HbA1c

<div><p>Objective</p><p>This study aimed to investigate differences between patients with type 1 and type 2 diabetes mellitus with erectile dysfunction (ED) evaluated with Rigiscan and if there were a correlation to age, duration of diabetes, BMI, sex hormones, lipids and HbA1c.</p><p>Research design and methods: A retrospective study on patients with type 1 diabetes (n=15), type 2 diabetes (n=17) and a control group (n=31) that underwent Rigiscan examination for ED. Age, BMI, blood pressure, sex hormones, lipids and HbA1c were recorded and analyzed between groups.</p><p>Results</p><p>Diabetes duration and HbA1C did not correlate with Rigiscan outcome. Rigiscan measures did not differ between patients with type 1 diabetes and control subjects besides from fewer erectile episodes (p<0.01) and lower tumescence activity units in base (p<0.05). By contrast, patients with type 2 diabetes differed significantly with respect to RigiScan parameters both in comparison with the type 1 diabetic patients and the control group. BMI had a strong correlation to number of erectile episodes, duration of erection, duration of erection > 60 % and rigidity activated unit (RAU) in tip and base. Age and HDL-cholesterol had a significant correlation with number of erectile episodes during night (p <0.05).</p><p>Conclusion</p><p>Our results indicate that erectile dysfunction in men with diabetes differ between type 1 and type 2 diabetes patients. Neither diabetes duration nor HbA1C correlated to grade of erectile dysfunction among patients with diabetes. Increased BMI might be an explanation to the increased rate of erectile dysfunction seen in patients with type 2 diabetes.</p></div

Comparison of Rigiscan parameters.

<p>Values reported are mean ± SD. Mann-Whitney U-test) was used to test the differences between the groups. Data was considered statistically significant at <i>P</i> < 0.05.</p

Baseline clinical characteristics of participants at group level.

<p>Values reported are mean ± standard deviation (SD). Mann-Whitney U-test) was used to test the differences between the groups. Data was considered statistically significant at <i>P</i> < 0.05.</p

Odin/SMR limb observations of stratospheric trace gases : level 2 processing of C1O, N2O, HNO3, and O3

The Sub-Millimetre Radiometer (SMR) on board the Odin satellite, launched on 20 February 2001, observes key species with respect to stratospheric chemistry and dynamics such as O-3, ClO, N2O, and HNO3 using two bands centered at 501.8 and 544.6 GHz. We present the adopted methodology for level 2 processing and the achieved in-orbit measurement capabilities of the SMR radiometer for these species in terms of altitude range, altitude resolution, and measurement precision. The characteristics of the relevant level 2 data versions, namely version 1.2 of the operational processor as well as versions 222 and 223 of the reference code, are discussed and differences are evaluated. An analysis of systematic retrieval errors, resulting from spectroscopic and instrumental uncertainties, is also presented

Molecularly imprinted polymers coupled to matrix assisted laser desorption ionization mass spectrometry for femtomoles detection of cardiac troponin I peptides

Molecularly imprinted polymers (MIPs) were combined to MALDI-TOF-MS to evaluate a selective enrichment (SE) method for the determination of clinically relevant biomarkers from complex biological samples. The concept was proven with the myocardial injury marker Troponin I (cTnI). In a first part, MIP materials entailed for the recognition of cTnI epitopes (three peptides selected) were prepared and characterized in dimensions (0.7-2\u3bcm), dissociation constants (58-817\u2009nM), kinetics of binding (5-60\u2009min), binding capacity (ca. 1.5\u2009\ub5g/mg polymer), imprinting factors (3\u2009&gt;\u2009IF\u2009&gt;\u20095) and selectivity for the peptide epitope. Then, the MIPs, incubated with cTnI peptides and spotted on the target with the DHB matrix, were assayed for the desorption of the peptides in MALDI-TOF-MS. The measured detection limit was ca. 300\u2009femtomols. Finally, the MIP-SE MALDI-TOF-MS was tested for its ability to enrich in the cTnI peptides from a complex sample, mimic of serum (i.e. 81 peptides of digested albumin). The MIP-SE MALDI-TOF-MS successfully enriched in cTnI peptides from the complex sample proving the technique could offer a flexible platform to prepare entailed materials suitable for diagnostic purposes. Copyright \ua9 2015 John Wiley &amp; Sons, Ltd.Molecularly imprinted polymers (MIPs) were combined to MALDI-TOF-MS to evaluate a selective enrichment (SE) method for the determination of clinically relevant biomarkers from complex biological samples. The concept was proven with the myocardial injury marker Troponin I (cTnI). In a first part, MIP materials entailed for the recognition of cTnI epitopes (three peptides selected) were prepared and characterized in dimensions (0.7\u20132\u3bcm), dissociation constants (58\u2013817\u2009nM), kinetics of binding (5\u201360\u2009min), binding capacity (ca. 1.5\u2009\ub5g/mg polymer), imprinting factors (3\u2009&gt;\u2009IF\u2009&gt;\u20095) and selectivity for the peptide epitope. Then, the MIPs, incubated with cTnI peptides and spotted on the target with the DHB matrix, were assayed for the desorption of the peptides in MALDI-TOF-MS. The measured detection limit was ca. 300\u2009femtomols. Finally, the MIP-SE MALDI-TOF-MS was tested for its ability to enrich in the cTnI peptides from a complex sample, mimic of serum (i.e. 81 peptides of digested albumin). The MIP-SE MALDI-TOF-MS successfully enriched in cTnI peptides from the complex sample proving the technique could offer a flexible platform to prepare entailed materials suitable for diagnostic purposes